Responses
Scientific Abstracts
Rheumatoid arthritis - other biologictreatment
SAT0142 Immunogenicity of the Novel Anti-Il-17A Antibody, Secukinumab, with Intravenous and Subcutaneous Dosing Regimens in Healthy Subjects and Patients
Compose a Response to This Article
Other responses
No responses have been published for this article.